论文部分内容阅读
目的探讨非小细胞肺癌(NSCLC)患者术后采用吉西他滨联合顺铂辅助化疗的疗效及其影响因素。方法选取2013年10月至2015年2月间湖北医药学院附属东风医院收治的行手术治疗的116例NSCLC患者根据采用的化疗方案不同分为观察组和对照组,采用吉西他滨联合顺铂化疗的86例患者为观察组,采用多西紫杉醇联合顺铂化疗的30例患者为对照组。引入COX回归模型对有关指标进行单因素及多因素分析,比较两组患者治疗前后疗效及影响其疗效的相关因素。结果观察组患者中,死亡10例,癌症复发及转移23例,6个月总体生存率为84.3%,与对照组的83.3%比较,差异无统计学意义(P>0.05)。患者术后出现III度以上血液毒性16例,贫血3例(8.6%)、白细胞减少2例(4.8%)、血小板减少5例(10.2%)、粒细胞减少6例(15.8%),与对照组比较,差异均无统计学意义(P>0.05)。经回归分析显示,临床分期及分化程度是影响患者近期疗效的有效指标,差异有统计学意义(P<0.05)。结论非小细胞肺癌患者术后采用吉西他滨联合顺铂辅助化疗有较高疾病控制率,但临床分期及分化程度是影响NSCLC患者近期疗效的主要因素。
Objective To investigate the efficacy and influential factors of gemcitabine combined with cisplatin adjuvant chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods One hundred and sixty-six patients with NSCLC who underwent surgical treatment at Dongfeng Hospital Affiliated to Hubei Medical College from October 2013 to February 2015 were divided into observation group and control group according to different chemotherapy regimens. Gemcitabine combined with cisplatin chemotherapy The patients were in the observation group. Thirty patients receiving docetaxel combined with cisplatin were the control group. The COX regression model was introduced to carry out univariate and multivariate analysis on the relevant indicators, and to compare the curative effect of the two groups before and after treatment and the related factors that affect the curative effect. Results In the observation group, 10 patients died, 23 patients had cancer recurrence and metastasis, and the overall survival rate at 6 months was 84.3%. There was no significant difference between the observation group and the control group (83.3%, P> 0.05). Thirteen patients (n = 16) had anemia, anemia (8.6%), leucopenia in 2 patients (4.8%), thrombocytopenia in 5 patients (10.2%) and neutropenia in 6 patients (15.8% There was no significant difference between the two groups (P> 0.05). The regression analysis showed that the clinical stage and degree of differentiation were effective indicators of short-term efficacy of patients, the difference was statistically significant (P <0.05). Conclusion Non-small cell lung cancer patients with gemcitabine plus cisplatin adjuvant chemotherapy have a higher rate of disease control, but the clinical stage and degree of differentiation is the main factor affecting the short-term efficacy of NSCLC patients.